Leerink Partnrs Weighs in on Zoetis' Q3 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS - Free Report) - Research analysts at Leerink Partnrs boosted their Q3 2025 earnings per share estimates for shares of Zoetis in a report released on Tuesday, May 6th. Leerink Partnrs analyst D. Clark now anticipates that the company will post earnings of $1.68 per share for the quarter, up from their previous forecast of $1.64. The consensus estimate for Zoetis' current full-year earnings is $6.07 per share. Leerink Partnrs also issued estimates for Zoetis' Q4 2025 earnings at $1.46 EPS, FY2025 earnings at $6.22 EPS, FY2026 earnings at $6.88 EPS, FY2027 earnings at $7.48 EPS and FY2028 earnings at $8.07 EPS.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same quarter in the previous year, the company posted $1.38 earnings per share. The firm's revenue for the quarter was up 1.4% compared to the same quarter last year.

ZTS has been the subject of several other reports. Stifel Nicolaus cut their price objective on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research report on Monday, April 14th. UBS Group cut their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Piper Sandler increased their price objective on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Finally, Barclays raised their target price on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Zoetis has an average rating of "Buy" and a consensus price target of $212.13.

Zoetis Trading Down 1.1%

Shares of ZTS stock traded down $1.73 on Friday, hitting $159.96. 4,243,109 shares of the stock traded hands, compared to its average volume of 2,492,973. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis has a twelve month low of $139.70 and a twelve month high of $200.33. The firm's 50-day moving average price is $157.27 and its two-hundred day moving average price is $165.95. The stock has a market capitalization of $71.37 billion, a PE ratio of 29.24, a PEG ratio of 2.78 and a beta of 0.94.

Hedge Funds Weigh In On Zoetis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZTS. Blue Barn Wealth LLC raised its stake in shares of Zoetis by 48.2% in the first quarter. Blue Barn Wealth LLC now owns 2,669 shares of the company's stock valued at $439,000 after acquiring an additional 868 shares in the last quarter. Ontario Teachers Pension Plan Board increased its holdings in Zoetis by 124.1% during the 1st quarter. Ontario Teachers Pension Plan Board now owns 9,421 shares of the company's stock worth $1,551,000 after purchasing an additional 5,218 shares during the period. Deutsche Bank AG raised its position in Zoetis by 4.5% in the 1st quarter. Deutsche Bank AG now owns 3,017,649 shares of the company's stock valued at $496,856,000 after purchasing an additional 128,675 shares in the last quarter. Chicago Partners Investment Group LLC boosted its stake in shares of Zoetis by 11.1% in the 1st quarter. Chicago Partners Investment Group LLC now owns 2,925 shares of the company's stock valued at $456,000 after buying an additional 292 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Zoetis by 3.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 3,503,690 shares of the company's stock worth $576,883,000 after buying an additional 109,335 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares of the company's stock, valued at $2,757,196.26. The trade was a 1.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock valued at $312,254 over the last quarter. 0.18% of the stock is owned by company insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.